Publications by authors named "Gaelle Laboure"

Claim this Profile
D
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study.
Thomas Chalopin, Elise Cellerin, Hélène Demarquette, Andréa Pieragostini, Cécile Sonntag

Blood Cancer J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Convalescent plasma transfusion for immunocompromised viremic patients with COVID-19: A retrospective multicenter study.
Marjolaine Destremau, Hélène Chaussade, Victor Hemar, Mathilde Beguet, Pantxika Bellecave, Gaelle Laboure

J Med Virol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.
Hervé Ghesquières, Fanny Cherblanc, Aurélien Belot, Sophie Micon, Krimo K Bouabdallah

Blood Adv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort.
Hervé Ghesquières, Cédric Rossi, Fanny Cherblanc, Sandra Le Guyader-Peyrou, Fontanet Bijou

BMC Public Health· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma.
Marie-Hélène Delfau-Larue, Axel van der Gucht, Jehan Dupuis, Jean-Philippe Jais, Isabelle Nel, Gaelle Laboure

Blood Adv· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.
Gaëlle Labouré, Stéphanie Dulucq, Myriam Labopin, Reza Tabrizi, Estelle Guérin

Biol Blood Marrow Transplant· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis